March 15, 2019 — Fujifilm Medical Systems USA announced it has fulfilled all U.S. Food and Drug Administration (FDA) regulatory requirements for three new image processing and software advancements for its digital mammography system, Aspire Cristalle. Specifically, S-View, Iterative Super-resolution Reconstruction (ISR) and Tomosynthesis Spot — innovative tools designed to meet the dual challenge of higher image quality and lower dose — are now commercially available in the United States.
The Aspire Cristalle system with these latest features will be showcased at Fujifilm's booth at both the National Consortium of Breast Centers (NCoBC) conference, March 15-20 in Las Vegas, and the Society of Breast Imaging (SBI) Symposium, April 4-7 in Hollywood, Fla.
The following three new features were designed for the Aspire Cristalle with digital breast tomosynthesis (DBT):
-
S-View: Enabling radiologists to view a synthesized 2-D image reconstructed from DBT, an S-View image can be used together with tomosynthesis slice image for both screening and diagnosis. The tool provides a high level of detail but low noise within the synthetic image, delivering images that are similar in appearance to 2-D. By using S-View images instead of dedicated 2-D, it is possible to reduce dose as much as about 50 percent for examinations (when only tomosynthesis exposure is performed instead of both 2-D and tomosynthesis exposures).
-
Iterative Super-resolution Reconstruction (ISR): A new reconstruction process derived from auto-recognition technologies, ISR aims to improve both image detail and noise characteristics compared to filtered backprojection techniques. An improvement on conventional iterative reconstruction techniques, ISR reconstructs images at a finer resolution than the readout data, leading to enhanced detail and reduced noise without compromising the speed of image acquisition.
-
Tomosynthesis Spot: Developed for an advanced view for tomosynthesis images, the technique focuses compression for a precise visualization of a specific area of concern.
The Aspire Cristalle digital mammography system offers the DBT option and dose-saving Hexagonal Close Pattern (HCP) image capture technology for 20 percent improvement in dose efficiency (compared to square pixel arrays). It offers a full-field digital mammography image pixel size of 50µm and features innovations to optimize contrast, enable low dose and decrease acquisition time, all while providing noticeable improvement to patient comfort with Fujifilm's patented Comfort Paddle.
For more information: www.fujimed.com
December 03, 2025 
